PMID- 36229299
OWN - NLM
STAT- MEDLINE
DCOM- 20221226
LR  - 20221226
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 31
IP  - 12
DP  - 2022 Dec
TI  - Long-Term Ambulatory Intravenous Milrinone Therapy in Advanced Heart Failure.
PG  - 1630-1639
LID - S1443-9506(22)01097-6 [pii]
LID - 10.1016/j.hlc.2022.09.004 [doi]
AB  - BACKGROUND: The role of intravenous (IV) inotropes in the treatment of ambulatory 
      patients with advanced heart failure (HF) remains controversial. METHODS: This 
      was a retrospective study of patients with advanced HF. Patients on home IV 
      milrinone, who remained on it for at least 3 months, were included. We compared 
      the data from 3 months before starting IV milrinone to 3 months after initiating 
      therapy. A subset of patients who remained on milrinone for 6 months or longer 
      was analysed separately. RESULTS: A total of 90 patients remained on continuous 
      IV milrinone for 3 months, and 55 patients were treated for 6 months or longer. 
      In both groups, improvements in cardiac index (1.86-2.25, p<0.001 and 1.9-2.38, 
      p<0.0001), New York Heart Association (NYHA) class (3.32-2.76, p<0.0001 and 
      3.25-2.72, p=0.001), and liver function were noted. In the 6-month group, there 
      was also a decrease in mean hospitalised days per patient (9.40 vs 4.12, p<0.001) 
      and an improved tolerance of beta blocker therapy (83.3% vs 98.1%, p=0.006). 
      CONCLUSION: Long-term IV use of milrinone is associated with improvement in 
      haemodynamics, functional class, tolerance of medical therapy, and decrease in 
      hospitalised days.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Shringi, Sandipan
AU  - Shringi S
AD  - Gill Heart Institute, Division of Cardiovascular Medicine, University of 
      Kentucky, Lexington, KY, USA.
FAU - Joshi, Shiksha
AU  - Joshi S
AD  - Gill Heart Institute, Division of Cardiovascular Medicine, University of 
      Kentucky, Lexington, KY, USA.
FAU - Suffredini, John M
AU  - Suffredini JM
AD  - Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
FAU - Schenk, Ashley
AU  - Schenk A
AD  - Gill Heart Institute, Division of Cardiovascular Medicine, University of 
      Kentucky, Lexington, KY, USA.
FAU - Rajagopalan, Navin
AU  - Rajagopalan N
AD  - Gill Heart Institute, Division of Cardiovascular Medicine, University of 
      Kentucky, Lexington, KY, USA.
FAU - Guglin, Maya
AU  - Guglin M
AD  - Indiana University School of Medicine, Krannert Institute of Cardiology, 
      Indianapolis, IN, USA. Electronic address: mguglin@iu.edu.
LA  - eng
PT  - Journal Article
DEP - 20221010
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - JU9YAX04C7 (Milrinone)
RN  - 0 (Cardiotonic Agents)
SB  - IM
MH  - Humans
MH  - *Milrinone/pharmacology
MH  - Cardiotonic Agents
MH  - Retrospective Studies
MH  - *Heart Failure/drug therapy
MH  - Hemodynamics
OTO - NOTNLM
OT  - Heart failure
OT  - Inotropes
OT  - Milrinone
EDAT- 2022/10/14 06:00
MHDA- 2022/12/27 06:00
CRDT- 2022/10/13 22:04
PHST- 2022/01/29 00:00 [received]
PHST- 2022/08/13 00:00 [revised]
PHST- 2022/09/01 00:00 [accepted]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/12/27 06:00 [medline]
PHST- 2022/10/13 22:04 [entrez]
AID - S1443-9506(22)01097-6 [pii]
AID - 10.1016/j.hlc.2022.09.004 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2022 Dec;31(12):1630-1639. doi: 10.1016/j.hlc.2022.09.004. Epub 
      2022 Oct 10.